Biotech Values

[apljack]

EYEN: Inasmuch as each indication being studied requires to be thoroughly evaluated, I agree. However, the point I (and the company, i suspect) is trying to make is that this is a new delivery device that does not require any review process. Once the device has established itself in the marketplace, what barriers to allowing its use to deliver established ophthalmologic solutions to the eye will there be? If there are no barriers, there may be any number of uses for the optejet in the clinic and demand may be strong to cross over from old technology (eye droppers) to this new technology.